Result for
Tag: variants
February 25, 2021
A Novel SARS-CoV-2 Variant of Concern B.1.526 Identified in New York
[Pre-print, not peer-reviewed] The prevalence of SARS-CoV-2 isolates with the E484K mutation, a key mutation of the B.1.351 variant, rose from 1.3% to 12.3% between November 2020 to mid-February 2021 in New York City. In a subset of 65 samples suspected to contain key mutations, 49 fell within a single novel lineage (B.1.526) characterized by…
February 24, 2021
SARS-CoV-2 B.1.1.7 Sensitivity to MRNA Vaccine-Elicited, Convalescent and Monoclonal Antibodies
[Pre-print, not peer-reviewed] An assessment of immune responses following a single dose of the Pfizer-BioNTech vaccine (BNT162b2) vaccine using pseudoviruses expressing the wild-type Spike protein or the B.1.1.7 spike protein showed that the vaccine-elicited antibodies modestly reduced activity against the B.1.1.7 variant. This reduction was also observed in sera from some convalescent patients and with…
February 23, 2021
Reduced Binding and Neutralization of Infection- and Vaccine-Induced Antibodies to the B.1.351 (South African) SARS-CoV-2 Variant
[Pre-print, not peer-reviewed] Antibodies collected from people who had been infected with SARS-CoV-2 or who had received the Moderna vaccine showed lower levels of binding to the SARS-CoV-2 B.1.351 variant (first described in South Africa) compared to the D614G variant that has been dominant globally. This effect was observed for antibodies from individuals with acute…
February 22, 2021
Increased Hazard of Mortality in Cases Compatible with SARS-CoV-2 Variant of Concern 2020121 – a Matched Cohort Study
[Pre-print, not peer-reviewed] Findings from a cohort study among people tested for SARS-CoV-2 in community settings in the UK suggest the SARS-CoV-2 B.1.1.7 variant strain is associated with a higher risk of mortality. The hazard ratio for mortality was 1.7 for the variant strain compared to infection with previously circulating strains. This represents an increase…
Densely Sampled Viral Trajectories Suggest Longer Duration of Acute Infection with B.1.1.7 Variant Relative to Non-B.1.1.7 SARS-CoV-2
[Pre-print, not peer-reviewed] A longitudinal assessment of SARS-CoV-2 viral loads from a sample of 65 individuals compared the viral dynamics between individuals with the B.1.1.7 variant (n=7) and non-variant strains. Individuals with the B.1.1.7 variant had a mean duration of the proliferation phase (time from first detection to peak viral load) of 5.3 days, a…
The Rise of SARS-CoV-2 Variant B.1.1.7 in Israel Intensifies the Role of Surveillance and Vaccination in Elderly
[Pre-print, not peer-reviewed] An analysis of over 300,000 RT-PCR samples collected in Israel between December 6th, 2020 and February 10th, 2021 in the general community and nursing homes found that the B.1.1.7 variant outcompeted the wildtype SARS-CoV-2 strain, representing 90% of positive tests. The variant was 45% more transmissible than wildtype. In addition, the transmission…
Decreased Neutralization of SARS-CoV-2 Global Variants by Therapeutic Anti-Spike Protein Monoclonal Antibodies
[Pre-print, not peer-reviewed] A study testing the ability of therapeutic monoclonal antibodies REGN10933 and REGN10987 to neutralize SARS-CoV-2 variants B.1.1.7, B.1.351, mink cluster 5, and COH.20G/677H found that REGN10987 maintained most neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins. REGN10933 was not effective against B.1.351, which may be due to…
February 18, 2021
Serum Neutralizing Activity Elicited by MRNA-1273 Vaccine — Preliminary Report
Neutralizing activity of sera from recipients of the 2-dose Moderna vaccine in the phase 1 trial (n=45) were similar against a SARS-CoV-2 pseudovirus bearing the spike protein from the original Wuhan-Hu-1 isolate, the D614G variant, as well as against 20E (EU1), 20A.EU2, N439K-D614G, and mink cluster 5 variants. In contrast, neutralizing titers against the D614G…
FDA-Authorized COVID-19 Vaccines Are Effective per Real-World Evidence Synthesized across a Multi-State Health System
[Pre-print, not peer reviewed] The Moderna and Pfizer vaccines were 89% effective (95% CI: 68-97%) in preventing SARS-CoV-2 infection occurring at least 36 days after the first dose in a 1:1 propensity score matched analysis of over 60,000 individuals in the US between December 2020 to February 2021. Among those subsequently diagnosed with COVID-19, vaccinated…
Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report
Neutralizing activity of sera from recipients of the 2-dose Pfizer vaccine (n=15, 20 serum samples) against wild-type SARS-CoV-2 (USA-WA1/2020) engineered with the full set of spike protein mutations of the B.1.351 variant was weaker than the USA-WA1/2020 strain by approximately two-thirds. Using 50% plaque reduction neutralization testing (PRNT50) on sera obtained 2-4 weeks after the…
Previous page Next page